Dynavax posts 2Q loss, weighed down by expenses (AP)

AP – Drug developer Dynavax Technologies Corp. said Friday that higher operating expenses, weak revenue and costs linked to a stock offering drove it to a second-quarter loss, reversing a year-ago profit.